Biomarkers in prostate cancer: What's new?

Current Opinion in Oncology

Volumn 26, Issue 3, 2014, Pages 259-264

  Sartori, David A ^a,b   Chan, Daniel W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Army Medical Department Center and School   (United States)

Author keywords

aggressiveness; biomarkers; genomics; prostate cancer; proteomics

Indexed keywords

BIOLOGICAL MARKER; KALLIKREIN; KALLIKREIN RELATED PEPTIDE 2; MITOCHONDRIAL DNA; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

CELL CYCLE PROGRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; DNA METHYLATION; FOOD AND DRUG ADMINISTRATION; GLEASON SCORE; HUMAN; NEEDLE BIOPSY; OCCULT CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR GENE; TUMOR GROWTH;

GENES, NEOPLASM; GENETIC MARKERS; HUMANS; MALE; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84899490062     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000065     Document Type: Review

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30.
2. Clegg L, Li F, Hankey B, et al. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology and End Results) Program population-based study. Arch Intern Med 2002; 162:1985-1993.
3. Martin DW, Starks AD, Ambs S. Biological determinants of health disparities in prostate cancer. Curr Opin Oncol 2013; 25:235-241.
4. Paquette E, Sun L, Paquette L, et al. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002; 60:756-759.
5. Jemal A, Ward E, Thun M. Declining death rates reflect progress against cancer. PLoS One 2010; 5:e9584.
6. Marta GN, Hanna SA, da Silva JLF, Carvalho HA. Screening for prostate cancer: an updated review. Expert Rev Anticancer Ther 2013; 13:101-108.
7. Trantham LC, Nielsen ME, Mobley LR, et al. Use of prostate-specific antigen testing as a disease surveillance tool following radical prostatectomy. Cancer 2013; 119:3523-3530.
8. Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: lost in transition. Washington, DC: National Academies Press; 2006.
9. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28:1117-1123.
10. Hansen J, Rink M, Graefen M, et al. Assays for prostate cancer. Mol Diagn Ther 2013; 17:1-8.
11. Lee YJ, Park JE, Jeon BR, et al. Is prostate-specific antigen effective for population screening of prostate cancer A systemic review. Ann Lab Med 2013; 33:233-241.
12. Wong LM, Neal DE, Johnston RB, et al. International multicenter study examining selection criteria for active surveillance in men undergoing radical prostatectomy. Brit J Cancer 2012; 107:1467-1473.
13. Van Neste L, Herman JG, Otto G, et al. The epigenetic promise for prostate cancer diagnosis. Prostate 2012; 72:1248-1261.
14. Vickers AJ, Lilja H. We need a better marker for prostate cancer. How about renaming PSA. Urology 2012; 79:254-255.
15. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:120-134.
16. NCCN. Clinical practice guidelines in oncology: prostate cancer. National comprehensive cancer network 2014; Version 1: Available from: NCCN.org. Detailed guidelines on the detection, prevention, risk stratification and treatment of patients.
17. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271:368-374.
18. Füzé ry A, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteom 2013; 10:13-26.
19. Hori S, Blanchet JS, McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int 2013; 112:717-728.
20. Loeb S, Sokoll L, Broyles DL, et al. Prospective multicenter evaluation of the Beckman Coulter prostate health index using WHO calibration. J Uro 2013; 189:1702-1706.
21. Lazzeri M, Abrate A, Lughezzani G, et al. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostatespecific antigen of 4-10 ng/mL and normal digital rectal examination. Urology 2014; 38:606-612.
22. Lazzeri M, Haese A, Abrate A, et al. Clinical performance of serum prostatespecific antigen isoform [-2]proPSA (p2PSA) and its derivatives %p2PSA and the prostate health index (phi) in men with a family history of prostate cancer: results from a multicenter European study, the PROMEtheuS project. BJU Int 2013; 112:313-321.
23. Heidegger I, Klocker H, Steiner E, et al. [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer and Prostatic Disease 2014; 17:70-74.
24. Scattoni V, Lazzeri M, Lughezzani G, et al. Head to head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol 2013; 190:496-501.
25. Sokoll LJ, Sanda MG, Feng Z, et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemol Biomarkers Prev 2010; 19:1193-1200.
26. Crawford ED, Rove KO, Trabulsi EJ, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1962 cases. J Urol 2012; 188:1726-1731.
27. Vlaeminck-Guillem V, Ruffion A, André J, et al. Urinary prostate cancer 3 test: toward the age of reason Urology 2010; 75:447-453.
28. Auprich M, Bjartell A, Chun FK-H, et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol 2011; 60:1045-1054.
29. Knezevic D, Goddard AD, Natraj N, et al. Analytical validation of the Oncotype DX prostate cancer assay-a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genom 2013; 14:690-702.
30. Cuzick J, Berney DM, Fisher G, et al. Prognostic value of cell cycle progression signature for a prostate cancer death in a conservatively managed needle biopsy cohort. Brit J Cancer 2012; 106:1095-1099.
31. Freedland SJ, Gerber L, Reid J, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiation Oncol Biol Phys 2013; 86:848-853.
32. Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013; 31:1428-1434.
33. McDunn JE, Li Z, Adam KP, et al. Metabolomic signatures of aggressive prostate cancer. Prostate 2013; 73:1547-1560.
34. Saylor PJ, Karoly ED, Smith MR. Prospective study of changes in the metabolomics profiles of men during their first three months of androgen deprivation therapy for prostate cancer. Clin Cancer Res 2012; 18:3677-3685.
35. Jung K, Reszka R, Kamlage B, et al. Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma. Int J Cancer 2013; 133:2914-2924.
36. Kami K, Fujimori T, Sato H, et al. Metabolomic profiling of lung and prostate tumor tissues by capillary electrophoresis time-of-flight mass spectrometry. Metabolomics 2013; 9:444-453.
37. Truong M, Yang B, Jarrad DF. Toward the detection of prostate cancer in urine: a critical analysis. J Urol 2013; 189:422-429.
38. Falzarano SM, Magi-Galluzzi C. ERG protein expression as a biomarker of prostate cancer. Biomarkers Med 2013; 7:851-865.
39. Bhavsar T, McCue P, Birbe R. Molecular diagnosis of prostate cancer: are we up to age Semin Oncol 2013; 40:259-275.
40. Salami SS, Schmidt F, Laxman B, et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 2013; 31:566-571.
41. Cornu JN, Cancel-Tassin G, Egrot C, et al. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Prostate 2013; 73:242-249.
42. Leyten GH, Hessels D, Jannick SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2:ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014; 65:534-542; http://dx.doi.org/10.1016.j.eur-uro.2012.11.014.
43. Heichman KA, Warren JD. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med 2012; 50:1707-1721.
44. Stewart GD, Van Neste L, Delvenne P, et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. Urol 2013; 189:1110-1116.
45. Desotelle J, Truong M, Ewald J, et al. CpG island hypermethylation frequently silences FILIP1L isoform 2 expression in prostate cancer. Urol 2013; 189:329-335.
46. Parr R, Mills J, Harbottle A, et al. Mitochondria, prostate cancer, and biopsy sampling error. Discov Med 2013; 15:213-220.
47. Verschoor ML, Ungard R, Harbottle A, et al. Mitochondria and cancer: past, present, and future. Biomed Res Int 2013; 2013:612369.
48. Voigt JD, Zappala SM, Vaughan ED, Wein AJ. The kallikrein panel for prostate cancer screening: Its economic impact. Prostate 2014; 74:250-259. doi:10.1002/pros.22746.
49. Carlsson S, Machino A, Schrö der F, et al. Predictive value of four kallikrein markers for pathologically insignificant compared to aggressive prostate cancer in radical prostatectomy specimens: results from the European randomized study of screening for prostate cancer section Rotterdam. Eur Urol 2013; 64:693-699.
50. Bjartell A. Next-generation prostate-specific antigen test: ready to use Eur Urol 2013; 64:700-702.